| dc.creator | Kantsadi A.L., Stravodimos G.A., Kyriakis E., Chatzileontiadou D.S.M., Solovou T.G.A., Kun S., Bokor É., Somsák L., Leonidas D.D. | en |
| dc.date.accessioned | 2023-01-31T08:30:20Z | |
| dc.date.available | 2023-01-31T08:30:20Z | |
| dc.date.issued | 2017 | |
| dc.identifier | 10.1016/j.jsb.2017.05.001 | |
| dc.identifier.issn | 10478477 | |
| dc.identifier.uri | http://hdl.handle.net/11615/74297 | |
| dc.description.abstract | 3-(C-Glucopyranosyl)-5aryl-1,2,4-triazoles with an aryl moiety larger than phenyl have been shown to have strong inhibitory potency (Ki values in the range of upper nM) for human liver glycogen phosphorylase (hlGP), a pharmacologically relevant target for diabetes type 2. In this study we investigate in a comparative manner the inhibitory effect of the above triazoles and their respective imidazoles on hlGPa. Kinetic studies show that the imidazole derivatives are 6–8 times more potent than their corresponding triazoles. We also seek to answer how the type of the aryl moiety affects the potency in hlGPa, and by determination of the crystal structure of rmGPb in complex with the triazole derivatives the structural basis of their inhibitory efficacy is also elucidated. Our studies revealed that the van der Waals interactions between the aryl moiety and residues in a hydrophobic pocket within the active site are mainly responsible for the variations in the potency of these inhibitors. © 2017 Elsevier Inc. | en |
| dc.language.iso | en | en |
| dc.source | Journal of Structural Biology | en |
| dc.source.uri | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85019078766&doi=10.1016%2fj.jsb.2017.05.001&partnerID=40&md5=8398f0ec729efdd32bb0d9cf7b076062 | |
| dc.subject | 3 (beta dextro glucopyranosyl) 5 (5,6,7,8 tetrahydronaphthalen 2yl) 1,2,4 triazole | en |
| dc.subject | 3 (beta dextro glucopyranosyl) 5 (naphthalen 2yl) 1,2,4 triazole | en |
| dc.subject | 5 (5,6,7,8 tetrahydronaphthalen 2 yl) 3 (2',3',4',6' tetra o acetyl beta dextro glucopyranosyl) 1,2,4 triazole | en |
| dc.subject | 5 (naphthalen 2 yl) 3 (2',3',4',6' tetra o acetyl beta dextro glucopyranosyl) 1,2,4 triazole | en |
| dc.subject | beta dextro glucopyranosyl triazole derivative | en |
| dc.subject | glycogen phosphorylase | en |
| dc.subject | imidazole derivative | en |
| dc.subject | triazole derivative | en |
| dc.subject | unclassified drug | en |
| dc.subject | enzyme inhibitor | en |
| dc.subject | glycogen phosphorylase | en |
| dc.subject | imidazole derivative | en |
| dc.subject | triazole derivative | en |
| dc.subject | Article | en |
| dc.subject | chemical interaction | en |
| dc.subject | controlled study | en |
| dc.subject | crystal structure | en |
| dc.subject | drug efficacy | en |
| dc.subject | drug potency | en |
| dc.subject | drug structure | en |
| dc.subject | enzyme activity | en |
| dc.subject | human | en |
| dc.subject | hydrogen bond | en |
| dc.subject | kinetics | en |
| dc.subject | priority journal | en |
| dc.subject | van der Waals interaction | en |
| dc.subject | X ray crystallography | en |
| dc.subject | antagonists and inhibitors | en |
| dc.subject | binding site | en |
| dc.subject | chemical phenomena | en |
| dc.subject | enzyme active site | en |
| dc.subject | enzymology | en |
| dc.subject | liver | en |
| dc.subject | non insulin dependent diabetes mellitus | en |
| dc.subject | Binding Sites | en |
| dc.subject | Catalytic Domain | en |
| dc.subject | Crystallography, X-Ray | en |
| dc.subject | Diabetes Mellitus, Type 2 | en |
| dc.subject | Enzyme Inhibitors | en |
| dc.subject | Glycogen Phosphorylase | en |
| dc.subject | Humans | en |
| dc.subject | Hydrophobic and Hydrophilic Interactions | en |
| dc.subject | Imidazoles | en |
| dc.subject | Kinetics | en |
| dc.subject | Liver | en |
| dc.subject | Triazoles | en |
| dc.subject | Academic Press Inc. | en |
| dc.title | van der Waals interactions govern C-β-D-glucopyranosyl triazoles’ nM inhibitory potency in human liver glycogen phosphorylase | en |
| dc.type | journalArticle | en |